Adlai Nortye (NASDAQ:ANL) Receives Buy Rating from HC Wainwright

Key Points

• HC Wainwright reiterated its “Buy” rating on Adlai Nortye and set a $20 price target, implying approximately 28% upside from the stock’s $15.62 price.
• Analyst sentiment is broadly positive: five analysts rate the stock Buy, one rates it Sell, and the consensus is “Moderate Buy” with a $29.20 target price.
• Institutional investors own 35.21% of the company, with several hedge funds recently establishing positions; CFO Xiaofeng Ye also sold shares to cover tax withholding obligations tied to vested equity awards.

Adlai Nortye (NASDAQ:ANL - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 28.04% from the company's current price.

Several other equities research analysts have also recently weighed in on the company. Oppenheimer started coverage on Adlai Nortye in a research note on Thursday, May 28th. They set an "outperform" rating and a $32.00 target price for the company. Weiss Ratings restated a "sell (e+)" rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Cantor Fitzgerald initiated coverage on Adlai Nortye in a research report on Monday, June 22nd. They issued an "overweight" rating on the stock. Wall Street Zen raised Adlai Nortye from a "hold" rating to a "buy" rating in a research note on Saturday, August 22nd. Finally, Loop Capital set a $49.00 price target on shares of Adlai Nortye in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.20.

Adlai Nortye Price Performance

Shares of ANL stock traded up $0.61 on Tuesday, hitting $15.62. The company's stock had a trading volume of 122,782 shares, compared to its average volume of 385,536. The company has a current ratio of 9.55, a quick ratio of 0.65 and a debt-to-equity ratio of 0.04. The stock's 50 day moving average is $12.62 and its 200-day moving average is $11.42. Adlai Nortye has a fifty-two week low of $0.88 and a fifty-two week high of $17.25.

Insider Buying and Selling

In other news, CFO Xiaofeng Ye sold 5,667 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the sale, the chief financial officer directly owned 147,757 shares of the company's stock, valued at $2,105,537.25. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Braidwell LP bought a new position in shares of Adlai Nortye during the 2nd quarter worth $9,145,000. ADAR1 Capital Management LLC purchased a new position in shares of Adlai Nortye in the first quarter worth about $816,000. Affinity Asset Advisors LLC purchased a new stake in shares of Adlai Nortye during the first quarter worth $1,140,000. Boone Capital Management LLC bought a new position in shares of Adlai Nortye in the second quarter worth $2,971,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Adlai Nortye during the 2nd quarter valued at $1,302,000. Hedge funds and other institutional investors own 35.21% of the company's stock.

Adlai Nortye Company Profile

Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.